Release Date: April 15, 2010
Expiration Date: April 14, 2011
Target Audience
This activity is intended for physicians, pharmacists, nurses, and case managers
from health plans, hospitals, provider groups, government programs, and other organizations
with an interest in pharmacoeconomics and health policy development. It may also
be useful to other clinicians and researchers working with public or private payers.
Statement of Need
Recently, the American Society of Clinical Oncology (ASCO) and the National Comprehensive
Cancer Network (NCCN) released new guidance on the use of breast cancer tumor markers
in breast cancer management strategies. Specifically, they provided new guidance
on the role of molecular diagnostics in breast cancer treatment planning. These
markers can provide a more comprehensive understanding of underlying tumor biology
leading to a more individualized approach in order to direct therapy. This activity
aims to discuss and review the parameters and methods currently used to risk stratify
women with early breast cancer based on risk for distal recurrence and likelihood
of response to adjuvant therapy in the context of recently released ASCO/NCCN guidelines
and other recent updates. This has implications toward managed care especially with
regard to development of clinical pathways in order to provide more consistent care
patterns leading to better quality of care.
Educational Objectives
Upon completion of this educational activity participants will be able to:
- Describe some of the evidence behind the NCCN and ASCO guidelines on the management
of early breast cancer related to tumor markers.
- Create a clinical pathway that addresses the use of gene expression assays in early
breast cancer.
- Determine the appropriateness of multi-gene assays in supporting adjuvant therapy
recommendations in early breast cancer.
Faculty Information and Disclosures
Frederick P. Smith, MD
Attending Medical Oncologist,
Sibley Memorial Hospital
Clinical Associate Professor,
Georgetown University School of Medicine
Washington, DC
Dr. Smith has disclosed that he serves as a consultant for Abraxis Oncology, Genomic
Health and Novartis.
Contributing Faculty/Disclosures
Sandra M. Swain, MD
Medical Director, Washington Cancer Institute
Washington Hospital Center
Washington, DC
Dr. Sandra Swain has no conflicts of interest to disclose which directly relate to
the content of this activity.
David Biggs, MD
Medical Oncology/Hematology Consultants, P.A.
Helen F. Graham Cancer Center
Newark, DE
Dr. David Biggs has no conflicts of interest to disclose which directly relate to
the content of this activity.
Stanley Marks, MD
Deputy Director of Clinical Services UPMC Cancer Center
Chief of Hematology/Oncology, UPMC Shady Side
Clinical Assistant Professor, University of Pittsburgh School of Medicine
Pittsburgh, PA
Dr. Stanley Marks has no conflicts of interest to disclose which directly relate
to the content of this activity.
Michael Schultz, MD
Director, The Breast Center at St. Joseph's Medical Center
TowsonTowson, MD
Dr. Michael Schultz has disclosed that he is on a speakers’ bureau for Genomic
Health, Inc.
William Smith, MD
Director, Department of Pathology Suburban Hospital
Bethesda, MD
Dr. William Smith has disclosed that he has received research support from the National
Institute Health.
Winston Wong, PharmD
Associate Vice President, Pharmacy Management
CareFirst BlueCross BlueShield
Baltimore, MD
Dr. Winston Dr. Winston Wong has no conflicts of interest to disclose which directly
relate to the content of this activity.
The planners and managers have no financial or other relationship to products
or devices with commercial interests related to the content of this CE/CME activity.
Astute Continuing Education: Erica Johansson-Neil, RN have nothing to disclose relating
to the content of this activity.
CEC partners and staff have no real or apparent conflicts of interest.
Instructions
To receive a statement of credit, you must:
- Review the full content of the activity and reflect upon its teachings.
- Complete the questions and evaluation within the activity.
Your statement of credit will be issued immediately upon successful completion of
the test and submission of the evaluation form.
Accreditation Statements
Physician
This activity has been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education
through the joint sponsorship of Creative Educational Concepts, Inc. (CEC) and Astute
Continuing Education. CEC is accredited by the ACCME to provide continuing medical
education for physicians.
CEC designates this educational activity for a maximum of 1.0 AMA PRA Category 1
Credits™. Physicians should only claim credit commensurate
with the extent of their participation in the activity.
Statements of credit will be issued online immediately following successful completion
of this activity.
Pharmacy
Creative Educational Concepts, Inc. (CEC) is accredited by the Accreditation Council
for Pharmacy Education as a provider of continuing pharmacy education.
This knowledge-based activity has been assigned ACPE #0245-0000-10-011-H01-P and
will award 1.0 contact hours (.10 CEUs) of continuing pharmacy education credit.
CEC complies with the Criteria for Quality for continuing education programming.
Nurses
Creative Educational Concepts, Inc. (CEC) is accredited as a provider of continuing
nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
CEC provides this activity for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider
or ANCC of any commercial products displayed in conjunction with an activity.
Case Managers
This activity has been approved for 1.0 clock hour through 12/31/10 by the Commission
for Case Manager Certification.
Fee
This activity is complimentary.
Disclosure Declaration
It is the policy of CEC and Astute Continuing Education to ensure independence,
balance, objectivity, scientific rigor, and integrity in their continuing education
activities.
Those involved in the development of this continuing education activity have made
all reasonable efforts to ensure that information contained herein is accurate in
accordance with the latest available scientific knowledge at the time of accreditation
of this continuing education activity. Information regarding drugs (e.g., their
administration, dosages, contraindications, adverse reactions, interactions, special
warnings, and precautions) and drug delivery systems is subject to change, however,
and the reader is advised to check the manufacturer's package insert for information
concerning recommended dosage and potential problems or cautions prior to dispensing
or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all presentation
materials produced by faculty, and all educational and advertising materials produced
by supporting organizations, prior to educational offerings. Approval of credit
for this continuing education activity does not imply endorsement by CEC or Quest
MedEd of any product or manufacturer identified.
Unlabeled Use Disclosure
This activity may include discussions of products or devices that are not currently
approved for use by the Food and Drug Administration (FDA), or are currently investigational.
Supporting Organization
This activity is supported by an educational grant from Genomic Health, Inc.
Viewing Requirements
PC
Internet Explorer 5.5 or greater
Firefox
Windows 2000 or greater
Sound Card & Speakers
800 x 600 Minimum Monitor Resolution
(1024 x 768 Recommended)
Flash Player Plug-in (9.0 or later)
* Adobe
Acrobat Reader
*Required to view Printable PDF Version
Mac OS 10.2.8
Safari
Firefox
Sound Card & Speakers
800 x 600 Minimum Monitor Resolution
(1024 x 768 Recommended)
Flash Player Plug-in (9.0 or later)
* Adobe
Acrobat Reader
In collaboration with 
|
